COVID-19. U07.1
Conditions
Interventions
Intervention 1: Intervention group: Country Standard Pharmaceutical Protocol + SOF/DCV (400mg/60mg) one tablet daily for 10 days. Intervention 2: Control group: Country Standard Pharmaceutical Protoc
Sponsors
Abadan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age =18 One of the following signs: Fever = 37.8°C at any one time, Dry cough, Severe fatigue, Dyspnea CT appearance compatible with COVID O2 Saturation 94% or less
Exclusion criteria
Exclusion criteria: Renal failure (eGFR < 30) Bradycardia (HR < 50) Taking amiodarone Previous sofosbuvir use Pregnancy/lactation Multi-organ failure on admission (2 organs or more, excluding lung) Requiring intubation on admission Significant arrhythmia in EKG Allergy to sofosbuvir or daclatasvir Not consenting to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recovery within 10 days of starting the drug. Recovery means: (no fever, no shortness of breath, no cough or improved, no fatigue or improved, tolerated oral nutrition) for 24 hours. Timepoint: Daily. Method of measurement: Clinical observation and examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Recovery within 14 days from start of medication. Timepoint: Daily. Method of measurement: Clinical observation and examination.;Rate of survival. Timepoint: Daily. Method of measurement: census report.;Days admitted in hospital. Timepoint: Daily since hospitalization time. Method of measurement: Based on patient's file.;Days intubated/under ventilator. Timepoint: Daily. Method of measurement: observation.;Days admitted in ICU. Timepoint: Daily. Method of measurement: Based on patient's file. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGholamali Eslami
Abadan University of Medical Sciences
Outcome results
None listed